4.6 Article

Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

期刊

出版社

WILEY
DOI: 10.1111/eci.13745

关键词

atrial fibrillation; chronic kidney disease; death; kidney failure; major bleeding; outcome; thromboembolism

资金

  1. Abbott Vascular Int
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol Myers Squibb
  8. Pfizer Alliance
  9. Alliance Daiichi Sankyo Europe GmbH
  10. Eli Lilly and Company
  11. Edwards
  12. Gedeon Richter Plc.
  13. Menarini Int. Op.
  14. MSD-Merck Co.
  15. Novartis Pharma AG

向作者/读者索取更多资源

The study examined the impact of renal impairment on patients with AF and found that impaired renal function was associated with a higher incidence of adverse events. Even in patients with indications for anticoagulants, severe renal impairment was linked to a reduction in prescription of these agents.
Background Atrial fibrillation (AF) and renal impairment share a bidirectional relationship with important pathophysiological interactions. We evaluated the impact of renal impairment in a contemporary cohort of patients with AF. Methods We utilised the ESC-EHRA EORP-AF Long-Term General Registry. Outcomes were analysed according to renal function by CKD-EPI equation. The primary endpoint was a composite of thromboembolism, major bleeding, acute coronary syndrome and all-cause death. Secondary endpoints were each of these separately including ischaemic stroke, haemorrhagic event, intracranial haemorrhage, cardiovascular death and hospital admission. Results A total of 9306 patients were included. The distribution of patients with no, mild, moderate and severe renal impairment at baseline were 16.9%, 49.3%, 30% and 3.8%, respectively. AF patients with impaired renal function were older, more likely to be females, had worse cardiac imaging parameters and multiple comorbidities. Among patients with an indication for anticoagulation, prescription of these agents was reduced in those with severe renal impairment, p < .001. Over 24 months, impaired renal function was associated with significantly greater incidence of the primary composite outcome and all secondary outcomes. Multivariable Cox regression analysis demonstrated an inverse relationship between eGFR and the primary outcome (HR 1.07 [95% CI, 1.01-1.14] per 10 ml/min/1.73 m(2) decrease), that was most notable in patients with eGFR <30 ml/min/1.73 m(2) (HR 2.21 [95% CI, 1.23-3.99] compared to eGFR >= 90 ml/min/1.73 m(2)). Conclusion A significant proportion of patients with AF suffer from concomitant renal impairment which impacts their overall management. Furthermore, renal impairment is an independent predictor of major adverse events including thromboembolism, major bleeding, acute coronary syndrome and all-cause death in patients with AF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据